Side-by-side · Research reference

FOXO4-DRIvsSNAP-8

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED12/45 cited

BHuman-MechanisticHUMAN-REVIEWED8/46 cited

FOXO4-DRI

Senolytic Peptide · D-Retro-Inverso

p53-TADMolecular targetBourgeois 2025

Pre-clinicalDevelopment stage

SQRoute (animal)

SQ · Animal models only

SNAP-8

Synthetic Octapeptide · Cosmetic Topical

TopicalRoute

8-AAPeptide length

SNAREPrimary target

Topical · Facial application · Twice daily

01Mechanism of Action

Parameter

FOXO4-DRI

SNAP-8

Primary target

FOXO4-p53 protein complex in senescent cellsBourgeois 2025 Tripathi 2021

SNARE complex (SNAP-25 competitive binding site)

Pathway

FOXO4-DRI binds disordered p53 transactivation domain → displaces FOXO4 → nuclear p53 exclusion → p53-mediated apoptosis in senescent cells

Acetyl octapeptide-3 → SNARE complex disruption → Reduced vesicular fusion → Decreased acetylcholine release → Muscle relaxation

Downstream effect

Selective apoptosis of senescent cells; clearance restores tissue homeostasisTripathi 2021 Alameen 2026

Transient reduction in neuromuscular signal transmission, decreased muscle contraction amplitude, wrinkle depth reduction

Feedback intact?

—

N/A — topical cosmetic, no systemic endocrine axis

Origin

D-retro-inverso modification — inverted amino acid sequence, D-amino acids for protease resistance

Synthetic peptide derived from N-terminal fragment of SNAP-25 protein (synaptosomal-associated protein 25 kDa)

Antibody development

—

02Dosage Protocols

Parameter

FOXO4-DRI

SNAP-8

Animal dose (mouse)

5 mg/kg

SQ injection, aged mouse model (testosterone restoration).

—

Frequency (animal)

Variable — single or intermittent dosing

Protocol-dependent; no standardised regimen.

—

Human equivalent (theoretical)

~0.4 mg/kg (28 mg / 70 kg adult)

Extrapolated using allometric scaling; no clinical validation.

—

Evidence basis

Animal / mechanistic

RCT, in vitro skin penetration studies

Route

SQ (animal)

No human route established.

—

Duration

Weeks to months (animal studies)

Senescent cell clearance observed within weeks.

—

Clinical status

No human trials completed

—

Typical concentration

—

2–10% in cosmetic formulationsLupin 2024 Raikou 2017

Commercial products typically use 5–10%.

Application frequency

—

Twice daily (morning and evening)Lupin 2024

Treatment duration

—

20–60 days for visible effectRaikou 2017

Skin microtopography improvements measured at 20-day intervals.

Formulation type

—

Oil-in-water emulsion, serum, cream

Application site

—

Facial skin — glabellar lines, crow's feet, forehead

Onset of effect

—

Visible reduction in wrinkle depth by day 20–28Raikou 2017

03Metabolic / Fat Loss Evidence

04Side Effects & Safety

Parameter

FOXO4-DRI

SNAP-8

Pulmonary hypertension risk

Senescent cell elimination promoted PH development/progression in rodent modelsBorn 2023

—

Context-dependent toxicity

Beneficial effects may be tissue/context-specific; elimination not universally protectiveBorn 2023

—

Off-target apoptosis

Theoretical risk of non-senescent cell apoptosis (selectivity not absolute)

—

Immune perturbation

Senescent cells contribute to immune surveillance; clearance effects unknown

—

Human safety unknown

No clinical trials — toxicity profile in humans not established

—

Cytotoxicity

—

Concentration-dependent antiproliferative effect observed in vitro; IC50 ~10 mg/mL (argireline, 6-AA analogue)

Commercial formulations typically use 0.05–0.1 mg/mL, well below cytotoxic threshold.

Skin irritation

—

Minimal; well-tolerated in clinical use

Peptide oxidation

—

Methionine residue susceptible to oxidation in formulation; may reduce efficacyKluczyk 2021

Formulation stability issue, not a direct adverse effect.

Systemic absorption

—

Negligible; peptide remains in stratum corneum and epidermisKraeling 2015

Hypersensitivity

—

Rare; no widespread allergic reactions reported

Absolute Contraindications

FOXO4-DRI

·Pulmonary hypertension or vascular disease (preclinical evidence of harm)Born 2023
·Pregnancy / lactation (no safety data)

SNAP-8

·Known hypersensitivity to acetyl octapeptide-3 or formulation excipients

Relative Contraindications

FOXO4-DRI

·Active malignancy (senescence as tumour suppressor mechanism)
·Wound healing / tissue repair (senescent cells involved in fibrosis resolution)

SNAP-8

·Active skin infections or open wounds at application site
·Neuromuscular disorders (theoretical concern, no documented cases)

05Administration Protocol

Parameter

FOXO4-DRI

SNAP-8

1. Pre-clinical route

Subcutaneous injection used in rodent models. No human administration protocol exists.

Wash face with gentle cleanser and pat dry. Remove makeup and surface oils to optimize peptide contact.

2. Reconstitution (animal)

Typically reconstituted in sterile saline or PBS for animal experiments. Stability data limited.

Apply 1–2 drops or pea-sized amount of SNAP-8 serum or cream to target areas (forehead, glabellar lines, crow's feet). Gently massage until absorbed.

3. Dosing schedule

Variable — single bolus or intermittent dosing over weeks. No standardised human protocol.

Twice daily — morning and evening. Allow 2–3 minutes for absorption before applying additional skincare products.

4. Clinical development status

No registered human trials. Commercialisation by Cleara Biotech (Netherlands) in development phase.

Apply before heavier creams or occlusive moisturizers. Peptides penetrate best from water-based serums on clean skin.

5. Safety monitoring (proposed)

Would require cardiovascular assessment, pulmonary function, immune panel, tumour surveillance if human trials proceed.

Store at room temperature, away from direct sunlight. Refrigeration may extend shelf life of formulations containing unstable peptides.

6. Duration

—

Consistent use for 20–60 days required for visible wrinkle reduction. Effects are temporary and reverse upon discontinuation.